ECE

Digital Locations Extends Its Agreement with Florida International University (FIU) to Continue Satenna™ Research

Retrieved on: 
수요일, 5월 29, 2024
Partnership, FIU, News, Computer, ECE, Florida International University, Research, Electricity

SANTA BARBARA, CA, May 29, 2024 (GLOBE NEWSWIRE) -- Digital Locations, Inc. (OTCMKTS:DLOC), the developer of Satenna™, a breakthrough technology that will deliver high-speed Internet from satellites directly to smartphones all over the world, today announced that it has extended its research agreement with Florida International University (FIU) to continue the Satenna™ research that it began a year ago.

Key Points: 
  • “I am extremely pleased with the progress that FIU has made in the development of Satenna™, said Digital Locations CEO Rich Berliner.
  • “I believe that continuing this partnership is the most certain way of bringing our breakthrough technology to the marketplace.
  • The Digital Locations research is being carried out within the FIU Department of Electrical and Computer Engineering (ECE) which encompasses a broad range of research and educational interests.
  • The research team assigned to the Satenna™ project consists of an impressive group of professors, graduate students, undergraduate students, and research assistants.

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

Retrieved on: 
목요일, 5월 9, 2024
Health, Drug, Endocrinology, ECE, Patient, Pharmaceutical industry

COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of Endocrinology being held May 11-14, 2024, in Stockholm.

Key Points: 
  • COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of Endocrinology being held May 11-14, 2024, in Stockholm.
  • Topics include an oral presentation of new 2-year results from a post-hoc analysis of the Phase 3 PaTHway Trial demonstrating sustained improvements in kidney function in adults with chronic hypoparathyroidism treated with TransCon PTH, as well as a symposium presentation on health and quality-of-life improvements in patients switching from rhPTH(1-84) to TransCon PTH as part of a compassionate use program.
  • “We are pleased to partner with leading experts in endocrinology to present this new, groundbreaking data showing the health and quality-of-life benefits of initiating or switching to TransCon PTH treatment,” said Aimee Shu, M.D., Ascendis Pharma’s Senior Vice President of Clinical Development, Endocrine Medical Sciences.
  • The full schedule of Ascendis presentations during ECE 2024 follow:

Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO

Retrieved on: 
화요일, 5월 7, 2024
ENDO, Cortex, Congress, European Society of Endocrinology, Patient, Hypoparathyroidism, Abstract, Rat, Novel, Acromegaly, Pharmacokinetics, Cohort, Combined, GRS, ECE, Trial of the century, Female, Pharmacodynamics, Fragility, Pharmaceutical industry

LYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 10th International Congress of the Growth Hormone Research Society (GRS), which is being held May 10-11 in Stockholm, Sweden, the 26th European Congress of Endocrinology (ECE), which is being held May 11-14 in Stockholm, Sweden, and at the 2024 Endocrine Society Meeting (ENDO), which is being held June 1-4 in Boston, Massachusetts.

Key Points: 
  • LYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 10th International Congress of the Growth Hormone Research Society (GRS), which is being held May 10-11 in Stockholm, Sweden, the 26th European Congress of Endocrinology (ECE), which is being held May 11-14 in Stockholm, Sweden, and at the 2024 Endocrine Society Meeting (ENDO), which is being held June 1-4 in Boston, Massachusetts.
  • These presentations cover both of Amolyt’s development programs, eneboparatide in Phase 3 for the treatment of hypoparathyroidism and AZP-3813 in Phase 1 for the treatment of acromegaly.
  • Details of the presentations are as follows:
    10th International Congress of the Growth Hormone Research Society (GRS) – May 10-11, Stockholm, Sweden
    Title: Additive Effect of Combined Treatment with the Small Peptide GH Receptor Antagonist, AZP-3813, and the Somatostatin Analog, Octreotide, in Decreasing IGF1 Levels in the Rat
    26th European Congress of Endocrinology (ECE) – May 11-14, Stockholm, Sweden
    Title: Increased Urinary Excretion of Calcium and Nephrolithiasis: Real-Life Data from the Epi-Hypo Cohort of Hypoparathyroidism Patients
    Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel, Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects
    Poster Display: 9:40am CEST on Sunday, May 12 to 3:30pm CEST on Tuesday, May 14, 2024
    Title: Additive Effect of Combined Treatment with the Small Peptide GH Receptor Antagonist, AZP-3813, and the Somatostatin Analog, Octreotide, in Decreasing IGF1 Levels in the Rat
    Title: Increased Bone Fragility Over Time in Women with Chronic Hypoparathyroidism: Real-world Data from the HypoparaNet Italian Cohort
    Poster Display: 9:40am CEST on Sunday, May 12 to 3:30pm CEST on Tuesday, May 14, 2024
    2024 Endocrine Society Meeting (ENDO) – June 1-4, Boston, Mass.
  • Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects
    Title: Increased Fragility of Bone Over Time in Female Patients with Chronic Hypoparathyroidism: Real-world Data from the Italian Cohort
    Title: Enhanced Ability of the Small Peptide GH Receptor Antagonist, AZP-3813, to Decrease IGF1 When Combined with the Somatostatin Analog, Octreotide
    Title: Eneboparatide, a Potent Stimulator of Urinary Calcium Reabsorption, Induces Prolonged Renal Cortex Retention and PTH1 Receptor Signalling

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Retrieved on: 
화요일, 5월 7, 2024
Safety, Patient, Neurocrine Biosciences, CAH, Abstract, Hydrocortisone, Congenital adrenal hyperplasia, ECE, Adrenal crisis, Treatment, Adrenocorticotropic hormone, Capsule, SAN, Incidence, Pharmaceutical industry

SAN DIEGO, May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14.

Key Points: 
  • SAN DIEGO, May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14.
  • Neurocrine Biosciences will be presenting several abstracts and posters at ECE 2024, including:
    Baseline Characteristics of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Pediatric, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist
    Baseline Characteristics of Adults with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Adult, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist
    CHAMPAIN study: Initial Results from a Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® (Efmody®) versus Plenadren, in Primary Adrenal Insufficiency,
    Biochemical Control with Dose Reduction in Chronic Glucocorticoid Therapy over 4 Years: A Phase III Extension Study of Chronocort (Efmody®) in the Treatment of Congenital Adrenal Hyperplasia (CAH)
    Incidence of Adrenal Crisis in Congenital Adrena Hyperplasia (CAH) Patients During a Prospective Monitored Long-Term study of Modified-Release Hydrocortisone (MRHC) Capsules, (Efmody)

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

Retrieved on: 
목요일, 4월 18, 2024
Congress, European Society of Endocrinology, Growth hormone, PES, LUMO, Abstract, MD, Doctor of Philosophy, GRS, ECE, Transgender hormone therapy, GHS, Growth

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.

Key Points: 
  • AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
  • Pediatric Endocrine Society ( PES ) Annual Meeting, held May 2-5, 2024, in Chicago, IL
    Abstract, OraGrowtH210 Trial (Phase 2): Oral LUM-201 Shows Similar Annualized Height Velocity to Daily rhGH in Moderate Pediatric Growth Hormone Deficiency (PGHD) with a 1.6mg/kg/day Dose and a Promising Investigational Safety Record, Andrew Dauber, MD, et al, to be presented in a poster session, Friday, May 3rd, 12:15-1:45 PM CT
    The 10th International Congress of the Growth Hormone Research Society ( GRS ), held May 10-11, 2024, in Stockholm, Sweden
    Abstract, Approaching the reality of restoring GH secretion and growth with the investigative oral growth hormone secretagogue (GHS) LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD), Peter Clayton, MD, PhD, et al, to be presented in an oral session, Friday, May 10th, 12:00-1:00 PM CET
    European Congress of Endocrinology ( ECE ) 2024, held May 11-14, 2024, in Stockholm, Sweden
    Abstract, Approaching the reality of restoring GH secretion and growth with the investigative oral growth hormone secretagogue (GHS) LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD), Peter Clayton, MD, PhD, et al, to be presented in an oral session, Sunday, May 12th, 4:20-6:00 PM CET
    “We are excited to share additional data analyses from our Phase 2 OraGrowtH Trials with the global endocrine community at these key medical meetings,” said Rick Hawkins, Lumos Pharma’s Chairman and CEO.
  • “Our Phase 2 data to date have demonstrated that, by augmenting the natural pulsatile secretion of growth hormone, our oral therapeutic candidate, LUM-201, produces comparable growth to injectable rhGH with significantly less exposure to circulating GH.
  • We believe this information will continue to resonate throughout the endocrine community and that oral LUM-201 could create a paradigm shift in the way PGHD and other growth hormone disorders are treated.”

Mercedes-Benz Q1 Marked by Solid Cash Generation and Top-End Model Changeovers 

Retrieved on: 
화요일, 4월 30, 2024
Automotive Manufacturing, Manufacturing, General Automotive, Automotive, EV, Electric Vehicles, Annual general meeting, Annual, Mercedes-Benz Group, Mercedes-Benz Mobility, Total, Car, Investment, Policy, Uncertainty, Research, Plant, ECE, GLC, Research and development, Worldwide, Acquisition, Mobility, XEV, CCR, Mercedes-Benz, Share repurchase, WLTP, Automotive industry

Current supply bottlenecks are on the way to easing in regard to the GLC and E-Class, with further improvements expected.

Key Points: 
  • Current supply bottlenecks are on the way to easing in regard to the GLC and E-Class, with further improvements expected.
  • Sales levels in the first quarter are seen as the trough, with second quarter volumes expected to be better.
  • Q1 is seen as the trough, with improvements expected over the second half of 2024, despite increasing ramp-up costs for charging infrastructure.
  • The cost of credit risk is seen improving from Q1 levels but is expected at an overall higher level compared to 2023.

ChildCare Education Institute Launches ADM119: Time Management Skills for Early Childhood Providers

Retrieved on: 
목요일, 3월 28, 2024
EST, Child care, Education, Job satisfaction, ECE, Work, Time management, CCEI, Catalog, Nursing

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- ChildCare Education Institute ® (CCEI), one of the largest online training providers dedicated exclusively to the early care and education workforce, is pleased to introduce its newest course, ADM119: Time Management Skills for Early Childhood Providers.

Key Points: 
  • ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- ChildCare Education Institute ® (CCEI), one of the largest online training providers dedicated exclusively to the early care and education workforce, is pleased to introduce its newest course, ADM119: Time Management Skills for Early Childhood Providers.
  • This course will teach child care providers how to make the most of their time!
  • Effective time management skills will help teachers leave work at the end of the day on time, in control, and satisfied with a job well done.
  • ADM119: Time Management Skills for Early Childhood Providers is a two-hour, beginner-level course and grants 0.2 IACET CEU upon successful completion.

ECS Cyber Ops Leader Adam Tischler Awarded Elastic’s 2023 Certified Professional of the Year

Retrieved on: 
목요일, 3월 28, 2024
Defense, Other Defense, Artificial Intelligence, Engineering, Technology, Government Technology, Manufacturing, Security, CISA, Growth, Science, Risk, ECA, ECS, Mentorship, Computer security, ECE, Data, Tischler, CDM, Government, Certification, Medical device

ECS, a leader in advanced technology, science, and engineering solutions, announced today that Adam Tischler , cyber operations leader at ECS, has been recognized as the 2023 Certified Professional of the Year by Elastic.

Key Points: 
  • ECS, a leader in advanced technology, science, and engineering solutions, announced today that Adam Tischler , cyber operations leader at ECS, has been recognized as the 2023 Certified Professional of the Year by Elastic.
  • Used across the federal and commercial sectors for security, observability, analysis, and data visualization, Elastic is the leading platform for search powered solutions.
  • Tischler has achieved every available Elastic certification: Elastic Certified Engineer (ECE), Elastic Certified Analyst (ECA), and Elastic Certified Observability Engineer (ECOE).
  • “Adam is a key leader on our CISA CDM team, not only in helping develop the platform, but training and mentoring his teammates.”
    “I'm honored to be named Elastic's Certified Professional of the Year,” said Tischler.

Elastic Announces 2023 Elastic Excellence Awards Winners

Retrieved on: 
수요일, 3월 27, 2024
Professional Services, Data Management, Security, Technology, Data Analytics, Software, CISM, Organization, Elastic, Comcast, ESTC, ECA, ECS, Certification, ECE, CISSP, Public sector, Auction

Elastic ® (NYSE: ESTC) (“Elastic”), the company behind Elasticsearch®, today announced the winners and honorees of its Elastic Excellence Awards .

Key Points: 
  • Elastic ® (NYSE: ESTC) (“Elastic”), the company behind Elasticsearch®, today announced the winners and honorees of its Elastic Excellence Awards .
  • The awards celebrate organizations and individuals demonstrating ingenuity and resilience by pushing the limits of data search, observability, and security with groundbreaking implementations.
  • “We’re excited to announce the 2023 Elastic Excellence Awards winners and acknowledge our amazing community and their work.”
    The 2023 Elastic Excellence Award winners and honorees are,
    This award recognizes use cases addressing social and humanitarian challenges for the betterment of the world.
  • BUSINESS TRANSFORMATION AWARD: This award recognizes organizations that are creating measurable company-wide added value with each of Elastic’s solutions.

Hyundai Mobis Unveils Electric Vehicle Solutions Elevating Electric Consumption Efficiency, Design, and Convenience

Retrieved on: 
목요일, 3월 14, 2024
EV, Attention, CUV, SUV, IVI, ECE, Atmosphere, Lighting, Hyundai, Lidar, KRX, LED, Rail transport

Suitable for SUVs and CUVs

Key Points: 
  • Suitable for SUVs and CUVs
    SEOUL, South Korea, March 14, 2024 /PRNewswire/ -- Fierce global competition is accelerating the advent of the electric vehicle (EV) era by improving electric consumption efficiency (ECE).
  • The Front Face refers to the front part of the vehicle, where the lamps, grille, and hood are located.
  • Hyundai Mobis has incorporated various cutting-edge technologies into this integrated module, including an aerodynamic system that reduces air resistance and improves ECE.
  • This technology is particularly beneficial for SUV and CUV electric vehicles, where lowering the vehicle height is challenging.